Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 08/14 03:35:43 pm
186.41 USD   +1.16%
11:48aALLERGAN : Appoints Neurobiology Expert Michael E. Greenberg, PhD to..
AQ
10:07aBIOCENTURY - MA : FDA, Allergan
AQ
08/10ALLERGAN : and Editas Medicine Announce Exercise of Options to Joint..
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Allergan : Allergans Botox gets US FDA green light to treat forehead lines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 04:15pm CEST

Allergan PLC (NYSE:AGN) has received the US Food and Drug Administration (FDA) approval for the use of Botox for the temporary improvement of moderate-to-severe forehead lines.

The latest approval makes the brand the first and only neurotoxin to be indicated for three facial treatment areas. It has already been approved for the treatment of "crow`s feet" and glabellar lines.

In a statement released today announcing the FDA approval, David Nicholson, the companys chief research and development officer said: Allergan recognizes that forehead lines are a top area of concern for patients.

(c) 2017 TBREAK MEDIA. ALL RIGHTS RESERVED. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
11:48aALLERGAN : Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board o..
AQ
10:07aBIOCENTURY - MANAGEMENT TRACKS : FDA, Allergan
AQ
08/10ALLERGAN : and Editas Medicine Announce Exercise of Options to Jointly Develop C..
AQ
08/09ALLERGAN : Trademark Application for "PRESBYSOL" Filed
AQ
08/09ALLERGAN : An Application for the Trademark "BIOCELL" Has Been Filed by Allergan
AQ
08/09ALLERGAN : Reports Outline Pharmaceutical Science Study Results from Allergan (F..
AQ
08/08ALLERGAN : Report of unscheduled material events or corporate event
PU
08/08ALLERGAN PLC : Change in Directors or Principal Officers (form 8-K)
AQ
08/08ALLERGAN : Appoints Neurobiology Expert Michael E. Greenberg, PhD to its Board o..
PR
08/03U.S. tax cuts prompt rethink by some 'inverted' companies
RE
More news
News from SeekingAlpha
05:08aTracking Seth Klarman's Baupost Group Holdings - Q2 2018 Update 
08/13Broyhill Asset Management Mid-Year Letter 2018 
08/11STOCKS TO WATCH : Any Privacy For Tesla? 
08/10Are Drug Stocks Starved Of Capital? 
08/10FDA OKs birth control app 
Financials ($)
Sales 2018 15 535 M
EBIT 2018 7 412 M
Net income 2018 -1 106 M
Debt 2018 23 084 M
Yield 2018 1,50%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,51x
EV / Sales 2019 5,28x
Capitalization 62 458 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 208 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC12.48%62 458
JOHNSON & JOHNSON-6.42%350 770
PFIZER13.00%239 423
NOVARTIS-0.87%209 596
ROCHE HOLDING LTD.-3.39%207 317
MERCK AND COMPANY17.42%175 715